Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Ladiratuzumab vedotin |
Trade Name | |
Synonyms | SGN-LIV1A |
Drug Descriptions |
Ladiratuzumab vedotin (SGN-LIV1A) is a conjugate of anti-zinc transporter LIV-1 antibody and monomethyl auristatin E (MMAE), which delivers the cytotoxic agent to LIV1-positive cells, resulting in antitumor activity (PMID: 25253783). |
DrugClasses | |
CAS Registry Number | 1629760-29-7 |
NCIT ID | C112001 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + Ladiratuzumab vedotin | Atezolizumab Ladiratuzumab vedotin | 0 | 1 |
Ladiratuzumab vedotin | Ladiratuzumab vedotin | 0 | 2 |
Ladiratuzumab vedotin + Pembrolizumab | Ladiratuzumab vedotin Pembrolizumab | 0 | 1 |
Ladiratuzumab vedotin + Trastuzumab | Ladiratuzumab vedotin Trastuzumab | 0 | 1 |